Any coronavirus vaccine-related development will be in the spotlight besides the regular pipeline and regulatory updates in the biotech sector.
: Recap of the Week’s Most Important Stories : Alexion Pauses Enrollment in COVID-19 Study on Ultomiris Alexion ( ALXN Quick Quote ALXN - Free Report) announced that it will pause further enrollment in the global phase III study of Ultomiris (ravulizumab-cwvz) in adults with severe COVID-19 requiring mechanical ventilation. This decision was based on the recommendation of an independent data monitoring committee (IDMC), following their review of data from a pre-specified interim analysis. A pre-planned interim analysis of the primary endpoint — survival at day 29 — once 122 patients completed the 29-day primary evaluation period was the basis of the recommendation.
The committee recommended pausing additional enrollment, as the interim analysis showed a lack of efficacy when Ultomiris was added to best supportive care compared to best supportive care alone. The study will continue for patients already enrolled, including the completion of all study visits and planned Ultomiris dosing, according to the study protocol.
Alexion currently carries a Zacks Rank #2 (Buy). You can see
. the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here : Aclaris Surges on Arthritis Trial Data Aclaris Therapeutics, Inc.’s ( ACRS Quick Quote ACRS - Free Report) shares skyrocketed 220% after it released positive preliminary top-line results from a 12-week, phase IIa trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-450, an investigational oral MK2 inhibitor, in subjects with moderate to severe rheumatoid arthritis (RA) (ATI-450-RA-201). The data showed that ATI-450 demonstrated durable clinical activity, as defined by a marked and sustained reduction in DAS28-CRP and the evaluation of ACR20/50/70 responses over 12 weeks. The mean change from baseline in DAS28-CRP score at week 12 was a 2.0 reduction in the treatment arm compared to a 0.35 increase in the placebo arm. The data support the progression of ATI-450 to phase IIb. ATI-450 was generally well tolerated. : Shares of Biohaven Down on Alzheimer's Disease Study Data Biohaven ( BHVN Quick Quote BHVN - Free Report) were down after it announced disappointing data from its phase II/III study of troriluzole as a symptomatic treatment in mild-to-moderate Alzheimer's disease (AD). This preliminary analysis showed that troriluzole is not efficacious as a symptomatic treatment in a mixed population of patients with mild and moderate AD. Troriluzole did not statistically differentiate from placebo at 48 weeks on the study's prespecified co-primary endpoints on the Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-cog) and the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) in study participants with mild-to-moderate AD. Troriluzole also did not differentiate from placebo on the key secondary measure of hippocampal volume assessed by magnetic resonance imaging (MRI) in the overall population. : Shares of clinical-stage biotechnology company Gritstone Surges on COVID-19 Vaccine Progress Gritstone Oncology, Inc. ( GRTS Quick Quote GRTS - Free Report) surged after it announced that it is advancing the development of a second-generation vaccine against SARS-CoV-2 with potential for both prolonged protection and potency against Spike mutants. Gritstone entered into a clinical trial agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to initiate clinical testing of this next-generation vaccine. A phase I study, expected to be conducted through the NIAID-supported Infectious Diseases Clinical Research Consortium (IDCRC), is in development. : Lexicon Up on Regulatory Updates on Sotagliflozin Lexicon Pharmaceuticals, Inc. ( LXRX Quick Quote LXRX - Free Report) gained after it received positive FDA regulatory feedback on sotagliflozin in response to a request made by the company following the completion of the SOLOIST and SCORED studies relating to the potential submission of a new drug application (NDA). Per the FDA feedback, the results of phase III studies, SOLOIST and SCORED, can support an NDA submission for an indication to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent visits for heart failure in adult patients with type 2 diabetes with either worsening heart failure or additional risk factors for heart failure. Performance
The Nasdaq Biotechnology Index gained 4.08% in the last four trading sessions. Among the biotech giants, Regeneron gained 5.56% during this period. Over the past six months, shares of Alexion have rallied 44.89%. (See the last biotech stock roundup here:
). Biotech Stock Roundup: Updates From REGN, GILD & VIR, CVAC Teams Up With BAYRY What's Next in Biotech?
Stay tuned for more pipeline and regulatory updates.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>